核心观点 业务结构调优业绩快速增长，现金充足保障分红 郑中设计(002811) 证券研究报告 装修装饰Ⅱ / 公司点评 / 2025.08.26 | 投资评级:增持(维持) | | | --- | --- | | 基本数据 | 2025-08-25 | | 收盘价(元) | 11.40 | | 流通股本(亿股) | 2.83 | | 每股净资产(元) | 4.67 | | 总股本(亿股) | 3.08 | 最近 12 月市场表现 -5% 20% 46% 71% 96% 121% 郑中设计 沪深300 分析师 毕春晖 SAC 证书编号：S0160522070001 bich@ctsec.com 联系人 陈悦明 chenym01@ctsec.com ❖ 风险提示：业务开拓不及预期；新签订单不及预期；宏观经济波动风险。 | 盈利预测 | | | | | | | --- | --- | --- | --- | --- | --- | | [币种Table_FinchinaSimple] (人民币) | 2023A | 2024A | 2025E | 2026E | 2027E | | 营业收入(百万元) | 1,09 ...

Core Points - The company's operating income decreased by 10.2% year-on-year, with pharmaceutical industrial revenue increasing by 23.07% and pharmaceutical commercial revenue decreasing by 37.82% [1][2] - The decline in pharmaceutical commercial revenue is attributed to the company's ongoing optimization of its business structure, leading to a reduction in low-margin and inefficient operations [1] - The net profit attributable to shareholders decreased by 7.83%, primarily due to reduced investment income from joint ventures and non-recurring gains [2] Company Overview - The company is engaged in the pharmaceutical industry, with a focus on both industrial and commercial segments [1] - The pharmaceutical commercial segment has been expanding innovative businesses such as hospital SPD services, which has contributed to the ongoing optimization of its business structure [1] Important Events - The company's board of directors convened on August 19, 2025, to approve the 2025 semi-annual report, with all directors present and voting in favor [3] - The board also approved revisions to governance-related systems, including internal control and management of executive compensation [5]

Investment Rating - The investment rating for the company is "Buy-A" with a 12-month target price of 52.8 CNY, compared to the current stock price of 45.42 CNY [4]. Core Views - The company demonstrated resilience in revenue generation despite a downturn in industry demand, achieving a revenue of 5.816 billion CNY in H1 2025, a year-on-year increase of 0.97% [2]. - The significant increase in net profit by 107.53% year-on-year to 436 million CNY in H1 2025 is attributed to improved gross margins, reduced expense ratios, and increased non-recurring gains [2][3]. - The company has optimized its business structure by reducing low-margin waterproofing material operations while enhancing high-margin retail segments [2]. Summary by Sections Revenue Performance - In H1 2025, the company reported a revenue of 5.816 billion CNY, with Q1 and Q2 revenue growth rates of 3.12% and -0.24% respectively [2]. - The revenue from home decoration wall paint reached 1.574 billion CNY, up 8.43% year-on-year, driven by a 5.44% increase in sales volume and a 2.78% increase in average price [2]. - The engineering wall paint revenue was 1.795 billion CNY, down 2.26% year-on-year, while the base material revenue was 1.733 billion CNY, up 10.40% year-on-year [2]. Profitability - The gross margin improved to 32.35% in H1 2025, an increase of 3.71 percentage points year-on-year, with Q2 gross margin at 33.10% [3]. - The company’s expense ratio decreased to 23.67%, down 1.57 percentage points year-on-year, with reductions in travel, sales personnel salaries, and advertising expenses [3]. - The net profit margin for H1 2025 was 7.48%, an increase of 3.87 percentage points year-on-year [3]. Future Projections - Revenue projections for 2025-2027 are 13.369 billion CNY, 14.674 billion CNY, and 16.016 billion CNY, representing year-on-year growth rates of 10.44%, 9.76%, and 9.15% respectively [8]. - Net profit projections for the same period are 811 million CNY, 971 million CNY, and 1.142 billion CNY, with year-on-year growth rates of 144.46%, 19.64%, and 17.67% respectively [8].

Core Insights - Ningbo Jifeng Automotive Parts Co., Ltd. reported a slight decline in revenue for the first half of 2025, with total revenue of 10.523 billion yuan, down 4.39% year-on-year, while net profit attributable to shareholders surged by 189.51% to 154 million yuan [1] - The revenue decline was attributed to the sale of Toledo Molding & Die LLC's performance in the previous year, not due to core business weakness, indicating successful asset optimization and strategic adjustments [1] - The company’s emerging business, particularly the passenger car seat segment, showed remarkable growth, with revenue reaching 1.984 billion yuan, doubling year-on-year due to sustained investment and market expansion [1] Business Performance - The customer base of the company has diversified, covering overseas luxury car manufacturers, domestic new energy vehicle leaders, traditional high-end joint ventures, and top independent car manufacturers [2] - As of July 31, 2025, the company secured 24 designated projects in the passenger car seat sector, with a total lifecycle value between 95.94 billion yuan and 100.64 billion yuan [2] - The company has increased its R&D personnel for passenger car seats by approximately 175 people as of June 30, 2025, and has applied for a total of 180 patents, with 103 already granted [2] Capacity Expansion - The company has made significant progress in capacity construction for passenger car seats, with multiple production bases completed and operational, including locations in Hefei, Changzhou, Wuhu, Fuzhou, Yiwu, Tianjin, and Changchun [3] - The company is collaborating with its subsidiary Grammer Aktiengesellschaft to advance global seat business, with a new production base in Southeast Asia already operational and a European base under construction [3] - The company’s proactive approach in R&D and market expansion has positioned it well to meet increasing market demands for seat comfort and intelligence [3] Emerging Business Growth - In addition to passenger car seats, the company’s other emerging businesses also performed well, with intelligent air vent revenue reaching 136 million yuan and car refrigerator revenue approximately 77 million yuan in the first half of 2025 [3] - The company has secured 13 orders for car refrigerator products and has successfully gained project designations for hidden door handle products from various clients [3] - The company’s strategy of diversifying product offerings while focusing on specific product details has enhanced its competitive edge in the market [4]

Core Viewpoint - The company anticipates a loss attributable to equity holders of approximately RMB 40 million to RMB 60 million for the six months ending June 30, 2025, which is an improvement compared to a loss of RMB 62.7 million in the same period last year [1] Summary by Relevant Sections - **Financial Performance** - The expected loss for the current period is between RMB 40 million and RMB 60 million, showing a reduction from the previous year's loss of RMB 62.7 million [1] - **Operational Adjustments** - The board attributes the improved loss situation to business structure optimization and enhanced cost control measures during the period [1] - **Market Conditions** - The company faces challenges in its market segment, with some clients continuing to focus on cost reduction and efficiency improvements, indicating a weak industry environment [1] - **Future Outlook** - The company acknowledges that more time is needed to reverse the loss situation despite the ongoing optimization and cost control efforts [1]

Core Insights - The overall performance of futures companies in China has improved in the first half of the year, with a total revenue of 18.68 billion yuan and a net profit of 5.07 billion yuan, reflecting a year-on-year growth of approximately 3.89% and 32% respectively [1][2] Group 1: Business Performance - In June, the total revenue of 150 futures companies reached 3.43 billion yuan, with a net profit of 990 million yuan [1] - The growth in performance is attributed to the continuous optimization of business structure, with a diversification of income sources reducing reliance on traditional brokerage services [1] - The increase in trading volume in the futures market has effectively offset the impact of declining commission rates [1] Group 2: Market Trends and Future Outlook - The recent rebound in prices of black commodities and new energy materials like industrial silicon and lithium carbonate is expected to further activate market transactions [2] - The favorable market conditions in July are anticipated to continue, providing a positive start for the second half of the year for futures companies [2] - The focus for futures companies in the second half will be on leveraging innovative services to support the stabilization and improvement of the real economy [2] Group 3: Challenges Ahead - The futures industry faces challenges such as complex global economic conditions and ongoing geopolitical conflicts, which introduce significant uncertainties in the commodity market [2] - The competitive landscape is increasingly polarized, with leading firms expanding their scale while smaller companies experience transformation pains and heightened survival pressures [2] - Stricter regulatory requirements and increased compliance costs are expected to raise operational management demands for futures companies [2]

Core Viewpoint - Shanghai Xiba Technology Co., Ltd. plans to adjust its investment in its associate company Hainan Shenneng New Energy Co., Ltd. to address the operational funding gap, involving a proportional capital increase followed by a zero-price capital reduction to exit the investment [1][2][3]. Summary by Sections 1. Overview of Related Transactions - The company intends to conduct a proportional capital increase in Hainan Shenneng, raising its registered capital from 200 million yuan to 2,946.186 million yuan, while maintaining the shareholding ratios of all shareholders [2][6]. - Following the capital increase, the company and Shanghai Electric Wind Power Group will exit Hainan Shenneng through a zero-price capital reduction, decreasing the registered capital to 2,504.2581 million yuan [2][9]. 2. Related Party Information - The actual controller and chairman of the company, Dr. Wang Wei, serves as a director of Hainan Shenneng, and board member Wang Shanjiong is a supervisor at Hainan Shenneng, establishing a related party relationship [5]. - Hainan Shenneng is not a dishonest entity and has no other significant relationships with the company beyond the mentioned individuals [5]. 3. Capital Increase Details - The capital increase will be executed at a price of 1 yuan per registered capital, with the company not planning to make actual contributions after the increase due to the subsequent planned capital reduction [6][8]. - The shareholding structure before and after the capital increase remains unchanged, with the total registered capital increasing significantly [6][8]. 4. Capital Reduction Details - The capital reduction will involve the company and Shanghai Electric Wind Power Group exiting Hainan Shenneng at zero consideration, with no restrictions or legal issues affecting the share transfer [9][10]. - The capital reduction will not involve the return of contributions, as it pertains to the portion of capital that has been subscribed but not yet paid [10]. 5. Impact on the Company - This transaction aligns with the company's strategic development and operational needs, optimizing the business structure and alleviating cash flow pressure without harming the interests of shareholders [10][11]. - The transaction is expected to have no significant impact on the company's consolidated financial statements [10]. 6. Approval Process - The independent directors and the board of directors have approved the transaction, which will require shareholder approval, with related parties abstaining from voting [11][12].

Core Viewpoint - The appointment of An Zhongtao as the new chairman of Taishan Property Insurance is expected to bring a new path to profitability for the company, which has faced continuous losses in recent years [1][3]. Company Leadership Change - An Zhongtao has been approved to take on the role of chairman, having previously been involved in the company's establishment and holding various positions within the organization [3][4]. - His return marks a significant change in leadership, as Taishan Insurance has seen multiple chairmen since 2019, with the latest chairman resigning due to work reasons [5][7]. Financial Performance - Taishan Insurance has reported cumulative losses exceeding 5.12 billion since 2021, with a net loss of 3.6 billion in 2022, which was a significant increase from a loss of 0.99 billion in 2021 [7]. - The company's net loss narrowed to 0.48 billion in 2023, and it reported a loss of 0.1 billion in the first quarter of 2024 [7]. - The comprehensive cost ratio for the first quarter of 2024 was 103.68%, indicating that premium income did not cover expenses [7]. Business Strategy and Opportunities - Experts suggest that optimizing the business structure and reducing reliance on traditional auto insurance while developing agricultural and liability insurance could be key to turning around the company's fortunes [8][9]. - The company’s insurance business revenue has shown signs of decline, with a 1.98% decrease in 2024 and a significant drop of over 20% in the first quarter of the current year [8][9]. Regulatory and Compliance Issues - Taishan Insurance has faced regulatory penalties for issues related to financial data accuracy, highlighting the need for improved compliance management [12]. - The company is encouraged to develop inclusive insurance products to meet the needs of grassroots and small enterprises, which represent a significant market opportunity [12]. Future Directions - The company aims to enhance its core competitiveness through a strategy of "four optimizations and four enhancements," focusing on professional, refined, intensive, and differentiated management [10][11]. - Recent policies are expected to create new development opportunities in the property insurance market, particularly in agricultural insurance and products tailored for small and micro enterprises [11][12].

Group 1 - The company has decided to terminate the control change plan and the A-share issuance plan after three years of planning, reflecting a proactive adjustment based on the current market environment and long-term development strategy [1] - The termination of the plans allows the management to focus on core business operations and strategic transformation, demonstrating a pragmatic attitude and strategic determination in response to market changes [1][3] - The company aims to concentrate resources on the high-growth potential medical device sector, having established a solid foundation in the medical device distribution field with a comprehensive supply chain network covering over 20 provinces and cities in China [2] Group 2 - The company has deepened strategic cooperation with top brands such as Siemens and Mindray Medical, laying a foundation for market expansion and service upgrades [2] - By actively divesting non-core assets and completing significant goodwill impairment, the company has effectively alleviated historical burdens, allowing for a focus on high-value areas [2] - The company achieved a revenue of 30.317 billion yuan in 2024, showcasing the resilience of its core business despite a challenging market environment [2] Group 3 - As a private enterprise, the company possesses natural advantages in decision-making efficiency, flexibility, and market sensitivity, which are reflected in its proactive adjustment of capital pathways [3] - The strategic focus on the medical device sector aligns with the industry's trend towards specialization, high value, and efficiency, providing the company with a broad space for future development [3] - The termination of the control change and capital increase plans marks a new phase in the company's strategic focus, laying a solid foundation for high-quality future development [3]

Core Viewpoint - The company plans to transfer 48.4213% equity stake in its subsidiary Zhong'an Bio to Jiangxi Twin Biological Technology Co., Ltd. for a transaction price of 115 million yuan, aiming to deepen strategic cooperation with aquaculture group clients and optimize asset and business structure [1] Group 1 - The transaction will result in the company holding a 20% equity stake in Zhong'an Bio after completion [1] - Zhong'an Bio will no longer be included in the company's consolidated financial statements following the transaction [1] - The transaction does not constitute a related party transaction or a major asset restructuring and is subject to approval by the company's shareholders' meeting [1]